+

WO2007116428A2 - Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis - Google Patents

Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis Download PDF

Info

Publication number
WO2007116428A2
WO2007116428A2 PCT/IT2007/000261 IT2007000261W WO2007116428A2 WO 2007116428 A2 WO2007116428 A2 WO 2007116428A2 IT 2007000261 W IT2007000261 W IT 2007000261W WO 2007116428 A2 WO2007116428 A2 WO 2007116428A2
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine
cystine
treatment
glutathione
haemodialysis
Prior art date
Application number
PCT/IT2007/000261
Other languages
French (fr)
Other versions
WO2007116428A8 (en
WO2007116428A3 (en
Inventor
Francesco Santangelo
Francesco Paolo Pilato
Original Assignee
Bio3 Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Research Srl filed Critical Bio3 Research Srl
Priority to MX2008012974A priority Critical patent/MX2008012974A/en
Publication of WO2007116428A2 publication Critical patent/WO2007116428A2/en
Publication of WO2007116428A8 publication Critical patent/WO2007116428A8/en
Publication of WO2007116428A3 publication Critical patent/WO2007116428A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Definitions

  • the subject of the present invention is an oral composition of cysteine or of its oxidized disulphide form (cystine) in mixture with an effective amount of glutathione for the prevention and treatment of oxidative stress deriving from haemodialysis treatment in patients affected by chronic renal insufficiency.
  • cysteine or of its oxidized disulphide form (cystine) in mixture with an effective amount of glutathione for the prevention and treatment of oxidative stress deriving from haemodialysis treatment in patients affected by chronic renal insufficiency.
  • the invention also relates to a medical device in the form of a kit comprising single- dose quantities of the composition referred to above and of a second composition of pure cystine or cysteine, said compositions being designed to be administered separately to a patient under haemodialysis so as to increase, in the initial step of extracorporeal circulation, the level of glutathione in the shortest time possible in order to contrast rapidly the oxidative stress resulting from haemodialysis treatment.
  • Oxidative stress is defined as an imbalance between the antioxidizing physiological systems of protection and the increased production of oxygen or nitrogen radicals by the cells of the immune system. The consequence may be damage to the molecular structure of the proteins, sugars, and lipids parallel to the damage to the cellular functionality that jeopardizes also the functionality of the vital organs themselves of the organism. Oxidative stress has been seen to be particularly manifest in patients affected by renal insufficiency and subjected to haemodialysis .
  • ROSs reactive oxygen species
  • oxidative stress causes a greater facility in regard to infections due to the defective immune response, amyloidosis, and accelerated atherosclerosis, on account of continuous activation of the immunocompetent cells.
  • This situation triggers an inflammatory response, with consequent continuous release of cytokines and lysosomal proteolytic enzymes, and stimulation of the production of free radicals: in practice, oxidative stress becomes a self-generating process, and induces a condition of chronic inflammation.
  • cardiovascular complications which constitute the main cause of death in patients affected by chronic renal insufficiency. At a local level, these complications present with alteration of the endothelium, accumulation of lipids, formation of thrombi and occlusion of the lumen.
  • N-acetylcysteine (see, for example, Kidney Int.,. Vol. 64 (2003), pp. 82-91; Current Med. Chem. , 2003, 10, pp. 1241-53).
  • the document No. WO 01/02004 describes the use of N- acetylcysteine by means of intravenous injection prior to and/or during haemodialysis treatment.
  • the inventor has been able to clarify that surprisingly the addition of a significant amount of glutathione to an oral composition of cystine or cysteine, used for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients affected by chronic renal insufficiency, introduces an unexpected synergistic effect with respect to the composition containing just cystine or cysteine alone and has an immediate influence, if taken in the initial step of extracorporeal circulation, on the immune functions thanks to its role of anti-oxidant and of scavenger of radicals, without awaiting hepatic synthesis .
  • glutathione a tripeptide constituted by glutamic acid, cysteine and glycine, performs many physiological functions, including the anti-oxidizing capacity, the storage and transportation of cystine, the synthesis of the desoxyribonucleotide and the regulation of the metabolism of leukotrienes and prostaglandins.
  • GSH is the substrate of GSH peroxidase, which deactivates the peroxides, the substrate of GSH dehydrogenase, which regenerates the anti- oxidizing molecules, such as ascorbate, and finally the substrate of GSH-S-transferase, which detoxifies the xenobiotics .
  • GSH glycosylcholine
  • cysteine with an effective amount of glutathione is preferred, but other substances known to have antioxidizing properties can possibly be added, such as, purely by way of example, taurine, lipoic acid, luteine, and vitamins A, C and E. Consequently, forming the subject of the present invention are compositions containing cystine or cysteine with an effective amount of glutathione, which can be administered by oral route, for the prevention and treatment of oxidative stress deriving from haemodialysis treatment in patients affected by chronic renal insufficiency. Said compositions will be prepared according to conventional methods well known in the pharmaceutical field, such as the ones described in ⁇ Remington' s Pharmaceutical Handbook", Mack Publishing ,Co. , N. Y., USA.
  • compositions of the invention will be normally administered before haemodialysis in order to contrast ⁇ 4 the fastest way possible the oxidative stress that is triggered when extracorporeal circulation starts, which will subsequently be kept under control with the mere administration of cystine or cysteine. It is preferable for said compositions to be administered in the form of composition with unit oral dose.
  • cystine or cysteine with glutathione can possibly be associated to non-toxic antioxidants that can be administered by oral route, in particular vitamins A, C and E, lycopene, lipoic acid, luteine, ascorbic acid and taurine. Vitamin E and taurine are preferred.
  • compositions may be in the form of tablets, capsules, oral preparations, powders, granules, lozenges, or re- constitutable powders, but preferably in the liquid form, as syrups, solutions or suspensions.
  • the solid compositions may contain: conventional excipients, for example binders, such as cellulose, mannitol, lactose; diluents, such as calcium carbonate, calcium phosphate and lactose; agents of compression; lubricants, such as magnesium stearate; disintegrating agents, such as starch, polyvinylpyrrolidone and starch derivatives; colouring agents; aromatizing agents and the like.
  • binders such as cellulose, mannitol, lactose
  • diluents such as calcium carbonate, calcium phosphate and lactose
  • agents of compression such as lubricants, such as magnesium stearate
  • disintegrating agents such as starch, polyvinylpyrrolidone and starch derivatives
  • colouring agents such as aromatizing agents and the like.
  • the liquid compositions may contain conventional excipients, for example suspending agents, such as sorbitol, methylcellulose, hydroxyethylcellulose, carboxyl-methylcellulose; preservatives, for example, methyl or propyl p- hydroxybenzoate or sorbic acid, and, if desired, conventional aromatizing or colouring agents.
  • suspending agents such as sorbitol, methylcellulose, hydroxyethylcellulose, carboxyl-methylcellulose
  • preservatives for example, methyl or propyl p- hydroxybenzoate or sorbic acid
  • aromatizing or colouring agents for example, aromatizing or colouring agents.
  • Example 1 Non-gastroresistant tablet containing:
  • Vitamin C 25.00 mg
  • a medical device in the form of a kit for separate administration, as syrup, of the composition with a base of cystine or cysteine and glutathione and of the composition with the just cystine or cysteine, at the start and end of haemodialysis .
  • the kit is constituted by a certain number of packs formed by pairs of contiguous single- dose containers to be separated from one another by tearing along pre-defined lines.
  • the containers are made of plastic material that are closed at the top by an aluminium foil or a removable polyethylene film.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Described herein is an oral pharmaceutical composition containing cystine or cysteine with glutathione, for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients affected by chronic renal insufficiency.

Description

ORAL PHARMACEUTICAL COMPOSITION CONTAINING CYSTINE OR CYSTEINE WITH GLUTATHIONE FOR THE PREVENTION AND TREATMENT OF OXIDATIVE STRESS RESULTING FROM HAEMODIALYSIS, AND MEDICAL DEVICE
FOR ADMINISTRATION THEREOF
***
The subject of the present invention is an oral composition of cysteine or of its oxidized disulphide form (cystine) in mixture with an effective amount of glutathione for the prevention and treatment of oxidative stress deriving from haemodialysis treatment in patients affected by chronic renal insufficiency.
The invention also relates to a medical device in the form of a kit comprising single- dose quantities of the composition referred to above and of a second composition of pure cystine or cysteine, said compositions being designed to be administered separately to a patient under haemodialysis so as to increase, in the initial step of extracorporeal circulation, the level of glutathione in the shortest time possible in order to contrast rapidly the oxidative stress resulting from haemodialysis treatment.
STATE OF THE ART Oxidative stress is defined as an imbalance between the antioxidizing physiological systems of protection and the increased production of oxygen or nitrogen radicals by the cells of the immune system. The consequence may be damage to the molecular structure of the proteins, sugars, and lipids parallel to the damage to the cellular functionality that jeopardizes also the functionality of the vital organs themselves of the organism. Oxidative stress has been seen to be particularly manifest in patients affected by renal insufficiency and subjected to haemodialysis .
The interpretation of this phenomenon is attributed to the bio-incompatibility between the circulating blood cells of the patient and the dialysis membranes, in addition to other phenomena, such as the chronic uremic state. This bio-incompatibility induces an excessive production of reactive oxygen species (ROSs) by the immune system, and at the same time the reduction in the antioxidizing capacity of the organism due to the loss of antioxidizing molecules, such as reduced glutathione (GSH) , vitamin A, vitamin C, and vitamin E through the filters of the dialytic membranes.
One of the consequences of this abnormal immune response is a condition of oxidative stress, which causes a greater facility in regard to infections due to the defective immune response, amyloidosis, and accelerated atherosclerosis, on account of continuous activation of the immunocompetent cells. This situation triggers an inflammatory response, with consequent continuous release of cytokines and lysosomal proteolytic enzymes, and stimulation of the production of free radicals: in practice, oxidative stress becomes a self-generating process, and induces a condition of chronic inflammation.
The main consequence of oxidative stress is constituted by cardiovascular complications, which constitute the main cause of death in patients affected by chronic renal insufficiency. At a local level, these complications present with alteration of the endothelium, accumulation of lipids, formation of thrombi and occlusion of the lumen.
At a systemic level, chronic oxidative stress stimulates the synthesis of proteins of the acute phase by the liver, at the expense of the synthesis of other proteins, such as albumin and transferrin: the consequence is malnutrition, further aggravated by the catabolic degradation of the muscular proteins and by the reduction in appetite.
Examples of treatment of oxidative stress with administration of products having anti- oxidizing activity have been reported. The product currently most widely used for the prevention and treatment of oxidative stress is N-acetylcysteine (see, for example, Kidney Int.,. Vol. 64 (2003), pp. 82-91; Current Med. Chem. , 2003, 10, pp. 1241-53). In particular, the document No. WO 01/02004 describes the use of N- acetylcysteine by means of intravenous injection prior to and/or during haemodialysis treatment.
According to Nakanishi et al.r Kidney Int.
March 2003; 63(3): 1137-40, the plasmatic concentration of cysteine and also of homocysteine increases in patients with chronic renal insufficiency subjected to dialysis.
Consequently, it would not seem logical to increase further the concentration of cysteine in these patients.
DESCRIPTION OF THE INVENTION
In a prior patent application, there has instead been proposed, for the prevention and treatment of oxidative stress, the direct therapeutic use of cystine or cysteine instead of their derivatives, for the preparation of a medicament to be administered by oral route.
Following upon further tests, the inventor has been able to clarify that surprisingly the addition of a significant amount of glutathione to an oral composition of cystine or cysteine, used for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients affected by chronic renal insufficiency, introduces an unexpected synergistic effect with respect to the composition containing just cystine or cysteine alone and has an immediate influence, if taken in the initial step of extracorporeal circulation, on the immune functions thanks to its role of anti-oxidant and of scavenger of radicals, without awaiting hepatic synthesis .
It is known, that glutathione, a tripeptide constituted by glutamic acid, cysteine and glycine, performs many physiological functions, including the anti-oxidizing capacity, the storage and transportation of cystine, the synthesis of the desoxyribonucleotide and the regulation of the metabolism of leukotrienes and prostaglandins.
GSH is the substrate of GSH peroxidase, which deactivates the peroxides, the substrate of GSH dehydrogenase, which regenerates the anti- oxidizing molecules, such as ascorbate, and finally the substrate of GSH-S-transferase, which detoxifies the xenobiotics .
The effect of GSH on the immune function is directly linked to its role as anti-oxidant and scavenger of radicals. This is because GSH is the best system for maintaining the state, of cellular oxido-reduction and on the other hand the integrity and function of the protein. Furthermore, the physiological importance of ROSs is also significant in regulating the functions of intracellular signalling and activation of the transcription factors encoded during the synthesis of pro-inflammatory molecules, for example cytokines and leukotrienes.
The use of cysteine with an effective amount of glutathione is preferred, but other substances known to have antioxidizing properties can possibly be added, such as, purely by way of example, taurine, lipoic acid, luteine, and vitamins A, C and E. Consequently, forming the subject of the present invention are compositions containing cystine or cysteine with an effective amount of glutathione, which can be administered by oral route, for the prevention and treatment of oxidative stress deriving from haemodialysis treatment in patients affected by chronic renal insufficiency. Said compositions will be prepared according to conventional methods well known in the pharmaceutical field, such as the ones described in λλRemington' s Pharmaceutical Handbook", Mack Publishing ,Co. , N. Y., USA.
The amount of cystine and of glutathione will depend upon various factors, such as the seriousness of the condition^ and the weight of the patient. However, a unit dosage will generally contain from 200 to 500 mg of cystine or cysteine in mixture with approximately from 10 to 100 mg of glutathione. The compositions of the invention will be normally administered before haemodialysis in order to contrast ±4 the fastest way possible the oxidative stress that is triggered when extracorporeal circulation starts, which will subsequently be kept under control with the mere administration of cystine or cysteine. It is preferable for said compositions to be administered in the form of composition with unit oral dose.
According to a further aspect of the invention, cystine or cysteine with glutathione can possibly be associated to non-toxic antioxidants that can be administered by oral route, in particular vitamins A, C and E, lycopene, lipoic acid, luteine, ascorbic acid and taurine. Vitamin E and taurine are preferred.
According to the invention, the compositions may be in the form of tablets, capsules, oral preparations, powders, granules, lozenges, or re- constitutable powders, but preferably in the liquid form, as syrups, solutions or suspensions.
The solid compositions may contain: conventional excipients, for example binders, such as cellulose, mannitol, lactose; diluents, such as calcium carbonate, calcium phosphate and lactose; agents of compression; lubricants, such as magnesium stearate; disintegrating agents, such as starch, polyvinylpyrrolidone and starch derivatives; colouring agents; aromatizing agents and the like. The liquid compositions may contain conventional excipients, for example suspending agents, such as sorbitol, methylcellulose, hydroxyethylcellulose, carboxyl-methylcellulose; preservatives, for example, methyl or propyl p- hydroxybenzoate or sorbic acid, and, if desired, conventional aromatizing or colouring agents.
Given below, purely by way of example, is a preferred formulation for solid composition.
Example 1 - Non-gastroresistant tablet containing:
Cysteine: 500.00 mg
Glutathione: 50.00 mg
Vitamin C: 25.00 mg
Lecithin of soya: 21.-50 mg Lactose: 25.00 mg
Avicel PH: 102 30.00
Maize starch: 30.00 mg
Magnesium stearate: 10.00 mg
Talcum: 15.00 mg Titanium dioxide: 2.50 mg
As mentioned previously, there has also been developed a medical device in the form of a kit for separate administration, as syrup, of the composition with a base of cystine or cysteine and glutathione and of the composition with the just cystine or cysteine, at the start and end of haemodialysis .
The kit is constituted by a certain number of packs formed by pairs of contiguous single- dose containers to be separated from one another by tearing along pre-defined lines. Preferably, the containers are made of plastic material that are closed at the top by an aluminium foil or a removable polyethylene film.

Claims

1. An oral pharmaceutical composition containing cystine or cysteine with glutathione for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients affected by chronic renal insufficiency.
2. The composition according to Claim 1, in which cystine or cysteine are administered in unit doses ranging from 500 to 1000 mg in mixture with an amount of approximately 10 to 100 mg of glutathione .
3. The composition according to Claim 1 or Claim 2, in which cystine or cysteine with glutathione are used in association with other substances, such as taurine, lipoic acid, luteine, and vitamins A, C and E.
4. A medical device in the form of a kit for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients affected by chronic renal insufficiency, characterized in that it comprises two oral pharmaceutical compositions to be administered separately to a patient undergoing haemodialysis treatment of which the first comprises cystine or cysteine with the addition of a significant amount of glutathione and the second only cystine or cysteine.
5. Use of a medical device according to Claim 4, in which the composition of cystine or cysteine with glutathione is administered before haemodialysis treatment and the one with cystine or cysteine is administered after said treatment.
6. A method for the prevention and treatment of oxidative stress resulting from haemodialysis in patients affected by chronic renal insufficiency, comprising the oral administration to said patients of an amount ranging from 500 to
1000 mg of cystine or cysteine in mixture with an amount ranging from 10 to 100 mg of glutathione before haemodialysis treatment and an amount ranging from 500 to 1000 mg of pure cysteine and/or cysteine after the same treatment.
PCT/IT2007/000261 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis WO2007116428A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2008012974A MX2008012974A (en) 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000206A ITRM20060206A1 (en) 2006-04-10 2006-04-10 ORAL PHARMACEUTICAL COMPOSITION CONTAINING CYSTINE OR CISTEIN WITH GLUTATHYATE FOR THE PREVENTION AND TREATMENT OF OXIDATIVE STRESS FROM HEMODIALYSIS AND MEDICAL ADMINISTRATION DEVICE
ITRM2006A000206 2006-04-10

Publications (3)

Publication Number Publication Date
WO2007116428A2 true WO2007116428A2 (en) 2007-10-18
WO2007116428A8 WO2007116428A8 (en) 2007-12-13
WO2007116428A3 WO2007116428A3 (en) 2008-03-13

Family

ID=38480485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000261 WO2007116428A2 (en) 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis

Country Status (4)

Country Link
KR (1) KR20090024673A (en)
IT (1) ITRM20060206A1 (en)
MX (1) MX2008012974A (en)
WO (1) WO2007116428A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527802A (en) * 2014-07-02 2016-01-06 Olimed Ltd Tablet with differentiated absorption
FR3092491A1 (en) * 2019-02-11 2020-08-14 Bretagne Chimie Fine Non-therapeutic oral use of a composition for whitening and / or lightening the skin comprising cystine and glutathione in a cystine / glutathione ratio ranging from 1.5 to 4
EP4216939A4 (en) * 2020-09-28 2024-10-23 Georgia Tech Research Corporation USE OF CYSTIN AND ITS DERIVATIVES AS ANTITHROMBOTIC AND THROMBOLYTIC AGENTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3484389D1 (en) * 1983-11-15 1991-05-08 Kyowa Hakko Kogyo Kk METHOD FOR PRODUCING A CONNECTION FROM ITS PRECURSOR USING AN ENZYMATICALLY ACTIVE BACTERY.
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
KR100390630B1 (en) * 1999-07-02 2003-07-07 이희발 Peritoneal dialysis solutions containing antioxidants
ITMI20032528A1 (en) * 2003-12-19 2005-06-20 Francesco Santangelo USE OF CYSTINE OR CISTEIN FOR PREVENTION AND THE

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527802A (en) * 2014-07-02 2016-01-06 Olimed Ltd Tablet with differentiated absorption
GB2527802B (en) * 2014-07-02 2019-10-16 Olimed Ltd An orally disintegrating tablet with differentiated absorption
FR3092491A1 (en) * 2019-02-11 2020-08-14 Bretagne Chimie Fine Non-therapeutic oral use of a composition for whitening and / or lightening the skin comprising cystine and glutathione in a cystine / glutathione ratio ranging from 1.5 to 4
WO2020165084A1 (en) * 2019-02-11 2020-08-20 Bretagne Chimie Fine Non-therapeutic oral use of a composition for whitening and/or lightening the skin comprising cystine and glutathione in a cystine-glutathione ratio ranging from 1.5 to 4
JP2022510729A (en) * 2019-02-11 2022-01-27 ブルターニュ シミ フィヌ Non-therapeutic oral use of a composition containing cystine and glutathione to whiten and / or lighten the skin with a cystine / glutathione ratio of 1.5-4.
JP7108796B2 (en) 2019-02-11 2022-07-28 ブルターニュ シミ フィヌ Non-therapeutic oral use of a composition for whitening and/or brightening the skin containing cystine and glutathione and having a cystine/glutathione ratio of 1.5-4
US11969494B2 (en) 2019-02-11 2024-04-30 Bretagne Chimie Fine Non-therapeutic oral use of a composition for whitening and/or lightening the skin comprising cystine and glutathione in a cystine-glutathione ratio ranging from 1.5 to 4
EP4216939A4 (en) * 2020-09-28 2024-10-23 Georgia Tech Research Corporation USE OF CYSTIN AND ITS DERIVATIVES AS ANTITHROMBOTIC AND THROMBOLYTIC AGENTS

Also Published As

Publication number Publication date
WO2007116428A8 (en) 2007-12-13
KR20090024673A (en) 2009-03-09
ITRM20060206A1 (en) 2007-10-11
MX2008012974A (en) 2008-12-18
WO2007116428A3 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
US7887852B2 (en) Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
AU2010234206B2 (en) Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds
JP5074661B2 (en) Liver cancer development / proliferation inhibitor
EP1935417A1 (en) Composition for use in prevention of hypoglycemic condition
RU2003122061A (en) ANTIATEROSCLEROTIC COMPOSITION CONTAINING CAROTINOIDS AND METHOD FOR INHIBITING OXIDATION OF LOW DENSITY Lipoprotein (LDL)
WO2007116428A2 (en) Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis
US20070197647A1 (en) Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients
US8362079B2 (en) Method for treating hemodialysis-related oxidative stress using cystine or cysteine
CA2382548C (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
EP1153609B1 (en) Amino acid-containing albumin preparations
US6713501B1 (en) Supplement for dialysis patients
CA2317038C (en) Supplement for dialysis patients
CN115666549B (en) Methods for treating vascular occlusion crisis associated with sickle cell disease
Daschner et al. Emergency dialysis in neonatal metabolic crises
AU2012243363A1 (en) Use of E-adenosylmethionine, vitamin E, and vitamin C for the prevention and treatment of cardiovascular dysfunction
WO1998030217A1 (en) Supplement for dialysis patients
Ersoy Antioxidant treatment in dialysis patients—importance of ferritin
Ala Transfusion of Red Cells
JPH04503806A (en) therapeutic agent
MX2015006685A (en) Use of a dha ester for prophylactic and/or curative treatment of drepanocytosis.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012974

Country of ref document: MX

Ref document number: 4082/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087027326

Country of ref document: KR

122 Ep: pct application non-entry in european phase

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载